Drug Approval | September 12, 2021
US FDA grants Soligenix Orphan Drug Designation for the treatment of T-cell lymphoma
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
HTL will build, validate and operate a botulinum manufacturing facility in the US
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The drug is also intended for the treatment of glioblastoma multiforme
This is Enzene Biosciences third biosimilar to be approved
Subscribe To Our Newsletter & Stay Updated
